EDSA News and Press, Edesa Biotech Inc. From 05/24/22

TORONTO, ON / ACCESSWIRE / May 24, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company has initiated enrollment for a second cohort of patients for the Phase 3 part of a Pha...

TORONTO, ON / ACCESSWIRE / May 19, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, will present virtually at the H.C. Wainwright Global In...

Edesa Biotech press release (NASDAQ:EDSA): Q2 GAAP EPS of -$0.33. At March 31, 2022, Edesa had working capital of $14.66 million. Cash and cash equivalents totaled $15.89 million. For further details see: Edesa Biotech GAAP EPS of -$0.33

TORONTO, ON / ACCESSWIRE / May 13, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and six months ended March 31, 2022 and provided an update on its busine...

Completion of enrollment is anticipated by calendar fourth quarter for the Phase 2b study of Edesa's potentially first-in-class, anti-inflammatory drug TORONTO, ON / ACCESSWIRE / April 28, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on ...

Edesa is one of 4 pharmaceutical companies that received a grant from the Canadian government to develop a drug to treat COVID-19. EB01 achieved all endpoints in phase 2 clinical trial in the treatment of patients with allergic contact dermatitis. In critically ill hospitalized pa...

TORONTO, ON / ACCESSWIRE / March 29, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointment of Jennifer M. Chao to the company's Board of Directors. "Ms. Chao's appointment to ...

TORONTO, ON / ACCESSWIRE / March 24, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq ...

Applied Genetic Technologies (AGTC) -24% after proposes stock offering to fund clinical programs. ZIM Integrated Shipping Services (ZIM) -15%. Dave (DAVE) -13% on Q4 earnings release. Edesa Biotech (EDSA) -13% on pricing $10.0M stock offering. Dermata Therapeutic...

Edesa Biotech (NASDAQ:EDSA) has slipped ~17% pre-market after announcing a ~$10M share offering priced at-the-market under Nasdaq rules. The biopharmaceutical company entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sal...